Holen Sie sich die Stockscreener-App
358.24
3.56%
-13.23
Schlusskurs vom Vortag:
$371.47
Offen:
$365.45
24-Stunden-Volumen:
319.77K
Relative Volume:
0.80
Marktkapitalisierung:
$10.60B
Einnahmen:
$417.30M
Nettoeinkommen (Verlust:
$225.03M
KGV:
47.88
EPS:
7.4815
Netto-Cashflow:
$237.38M
1W Leistung:
+1.93%
1M Leistung:
+10.31%
6M Leistung:
+35.18%
1J Leistung:
+139.23%
1-Tages-Spanne:
$353.75
$371.99
1-Wochen-Bereich:
$345.14
$373.31
52-Wochen-Spanne:
$136.73
$382.54
Krystal Biotech Inc Stock (KRYS) Company Profile
Firmenname
Krystal Biotech Inc
Sektor
Branche
Telefon
(412) 586-5830
Adresse
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
358.24 | 9.98B | 417.30M | 225.03M | 237.38M | 7.4815 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-01-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-05 | Eingeleitet | Jefferies | Buy |
| 2024-08-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-12 | Eingeleitet | Citigroup | Buy |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2023-02-28 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-18 | Eingeleitet | BofA Securities | Buy |
| 2021-07-20 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-18 | Eingeleitet | B. Riley FBR | Buy |
| 2020-06-04 | Eingeleitet | Evercore ISI | Outperform |
| 2019-09-24 | Eingeleitet | Goldman | Neutral |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-24 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-30 | Eingeleitet | Guggenheim | Buy |
| 2018-09-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Krystal Biotech Inc Aktie (KRYS) Neueste Nachrichten
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism - Stocktwits
Krystal Biotech Inc (MIL:1KRYS) Stock Price, Trades & News - GuruFocus
Krystal Biotech, Inc. (KRYS) Stock Analysis: Exploring The 15.87% Upside Potential - DirectorsTalk Interviews
Krystal Biotech Insider Sold Shares Worth $8,227,953, According to a Recent SEC Filing - marketscreener.com
State of Wyoming Buys New Stake in Krystal Biotech, Inc. $KRYS - MarketBeat
Should Surging Vyjuvek-Driven Earnings Reshape How Krystal Biotech (KRYS) Investors View Its Risk Profile? - simplywall.st
Krystal Biotech (KRYS) Has a New Rating from RBC Capital - The Globe and Mail
Krystal Biotech (NASDAQ:KRYS) Upgraded to "Moderate Buy" at Royal Bank Of Canada - MarketBeat
Krystal Biotech (KRYS) Director Dino Rossi Sells 25,000 Shares - GuruFocus
Krystal Biotech(KRYS.US) Director Sells US$8.23 Million in Common Stock - Moomoo
Krystal Biotech (KRYS) Advances 1.2% to $332.27, Holding Ground Above Key SupportAggressive Growth Picks - vinanet.vn
Krystal Biotech (NASDAQ:KRYS) director Dino Rossi sells $8.2m shares - Investing.com Australia
Dino Rossi Sells 25,000 Shares of Krystal Biotech (NASDAQ:KRYS) Stock - MarketBeat
Krystal Biotech, Inc. SEC Filing (Aug 14, 2026) - Stock Titan
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More - The Globe and Mail
RBC Capital Initiates Krystal Biotech(KRYS.US) With Buy Rating, Announces Target Price $400 - moomoo.com
KRYS Looks 0.5% Undervalued on GF Value™ - GuruFocus
Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says - marketscreener.com
KRYS Initiates Coverage by RBC Capital -- Rating Set to Outperfo - GuruFocus
Krystal Bio wins bullish view at RBC Capital Markets (KRYS) - Seeking Alpha
Here Are Friday’s Top Wall Street Analyst Research Calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, Sandisk, T-Mobile US, Wayfair, and More - Yahoo Finance
RBC Initiates Krystal Biotech at Outperform, With $400 Price Target - marketscreener.com
KRYSTAL BIOTECH, INC. : RBC INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $400 - Bitget
Krystal Biotech (KRYS) Earnings And Pipeline Progress Put Valuation Back In Focus - Sahm
Krystal Biotech, Inc. (KRYS) Stock forecasts - Yahoo Finance UK
Wolfe Research Maintains Krystal Biotech(KRYS.US) With Hold Rating - Moomoo
Trading Systems Reacting to (KRYS) Volatility - news.stocktradersdaily.com
Bank of America Corp DE Increases Stock Position in Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech (KRYS) Q2 2026 Earnings Call Transcript - The Globe and Mail
If You Invested $1000 In Krystal Biotech Stock 5 Years Ago, You Would Have This Much Today - Benzinga
Renaissance Technologies LLC Has $2.48 Million Stock Position in Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech, Inc. (KRYS) Stock Analysis: Exploring a 17% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Krystal Biotech (KRYS) Stock May Be Fully Valued After Its 5x Run - Yahoo Finance
Krystal Biotech Inc (KRYS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Krystal Biotech (NASDAQ:KRYS) Upgraded at Chardan Capital - MarketBeat
Krystal Biotech, Inc. (KRYS) Stock Forecasts - Yahoo Finance
California State Teachers Retirement System Has $6.76 Million Holdings in Krystal Biotech, Inc. $KRYS - marketbeat.com
Krystal Biotech, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:KRYS) 2026-08-05 - Seeking Alpha
Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus - Yahoo Finance
Citi Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $386 - Moomoo
Krystal Biotech, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Brokers Issue Forecasts for Krystal Biotech FY2026 Earnings - MarketBeat
Krystal Biotech Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Krystal Biotech Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Krystal Biotech Inc (KRYS) (Q2 2026) Earnings Call Highlights: VYJUVEK Sales Surge 24% as ... By GuruFocus - Investing.com Canada
Krystal Biotech Inc (KRYS) (Q2 2026) Earnings Call Highlights: V - GuruFocus
Is Krystal Biotech (KRYS) Overvalued After Q2 Earnings Beat? EPS of $1.85 & Revenue of $119.2M; GF Score: 54/100 - GuruFocus
Why Is Krystal Biotech (KRYS) Dropping 7.0%? - AlphaStreet
Krystal Biotech stock falls 7% on revenue miss despite earnings beat - Investing.com South Africa
krystal biotech vyjuvek revenue rises 24 percent - grafa.com
Finanzdaten der Krystal Biotech Inc-Aktie (KRYS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):